Press Releases

Newsroom
In the News
Press Releases
Resources for Journalists

Press Releases

Share
Share
and/or
493 News Releases found
Memorial Sloan Kettering and Paige.AI

MSK was recently in the news regarding our relationship with a technology spin-off company called Paige.AI.
Memorial Sloan Kettering Cancer Center Announces Conflict of Interest Task Force

Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.
Ralph Lauren Center for Cancer Care to Formally Join Memorial Sloan Kettering

The Ralph Lauren Center for Cancer Care, a Harlem-based cancer prevention and treatment program, is expected to more closely align with Memorial Sloan Kettering Cancer Center (MSK) in 2019 pending the approval of the New York State Department of Health and other state agencies. The filing deepens the longstanding partnership between MSK and the Ralph Lauren Center. 
Kenneth Manotti, Senior Vice President and Chief Development Officer at MSK
Kenneth Manotti Named Senior Vice President and Chief Development Officer at Memorial Sloan Kettering Cancer Center

Kenneth Manotti has been named Senior Vice President and Chief Development Officer at Memorial Sloan Kettering Cancer Center (MSK).
J. Ted Gerstle
Renowned Pediatric Surgeon J. Ted Gerstle Named Chief of the Pediatric Surgery Service at Memorial Sloan Kettering Cancer Center

Pediatric surgeon J. Ted Gerstle, MD, FACS, FRCS, has been named the new Chief of the Pediatric Surgery Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK).
Kreg Koford Joins Memorial Sloan Kettering as Senior Vice President of Supply Chain and Sustaining Care Services

Memorial Sloan Kettering Cancer Center (MSK) has announced that Kreg Koford has been named MSK's Senior Vice President of Supply Chain and Sustaining Care Services. Mr. Koford assumes his new role at MSK on July 9, 2018.
Memorial Sloan Kettering Expands Its Footprint in Northern New Jersey

After more than two decades of providing outstanding cancer care to the people of New Jersey, Memorial Sloan Kettering announced today that its newest outpatient treatment center, in Bergen County, will welcome new patients in the coming weeks. In recognition of its debut, MSK’s leadership, joined by members of the community and local elected officials, gathered at the Montvale site to unveil MSK Bergen, a sleek, modern, technology-filled 110,000-plus-square-foot clinical program located on Summit Avenue, mere minutes from the Garden State Parkway.
Distinguished Chemist Selected to Lead the Tri-Institutional Therapeutics Discovery Institute

Peter T. Meinke will take the Tri-I TDI into the next phase of growth.
MSK Physician-in-Chief José Baselga, MD, PhD
Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer

The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer. Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented this data, from the SANDPIPER trial, in a press conference at the annual meeting of the American Society of Clinical Oncology. This combination of a mutant-selective PI3K inhibitor and a selective estrogen receptor degrader halted the growth of advanced breast cancer for two months longer than hormone therapy alone and decreased the chance of cancer worsening by 30 percent.
Zsofia Stadler, MD, clinic director of the Clinical Genetics Service and a medical oncologist
Genomic Markers Can Predict the Presence of Lynch Syndrome across a Broad Spectrum of Cancers

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.